Attovia Therapeutics Earnings Call Transcripts

Fiscal Year 2026

Morgan Stanley 24th Annual Global Healthcare Conference

The session highlighted rapid progress in developing modular nanobody-based biologics for immune-mediated diseases, with ATTO-1310 showing strong early efficacy and safety in chronic itch. Upcoming phase II trials target large unmet needs, while the pipeline expands into bispecific and trispecific assets, all supported by a robust financial position.

Read full transcript →